Takeda has put forward a new bid for Shire, increasing the cash portion of the deal.
Based on Takeda’s current market capitalisation, Shire’s shareholders would own around 49% of the new group.
“Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal.“
The new bid proposal represents a premium of around 58%, replacing an earlier offer of £28.75 per share, and £17.75 per share in cash.
Takeda believe the new proposal would mean that Shire shareholders would hold a meaningful stake in a leading global biopharmaceutical company, and it represents an opportunity which will reflect an increase in value and a material increase in the cash component of the consideration mix.
Shire’s board is now considering its position and will make an announcement in due course.See all the latest jobs in Pharmaceutical